AcelRx Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.08.17	Gainers & Losers Of Aug.2: ONCE, ILMN, XENT, NOVN, FLKS... (RTTNews)
02.08.17	Gainers & Losers Of August 1: OXFD, ENZY, ZYNE, GERN, ACRX... (RTTNews)
01.08.17	AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
01.08.17	AcelRx Pharmaceuticals Reports Successful Outcome of ZALVISO Phase 3 IAP312 Study on Device Functionality (PR Newswire)
01.08.17	Gainers & Losers Of July 31: SBBP, AKCA, ACRX, ICPT, ZYNE... (RTTNews)
31.07.17	AcelRx Pharmaceuticals to Hold a Conference Call and Webcast on Tuesday, August 1st to Discuss ZALVISO Phase 3 Top-line Data and Quarterly Financial Results (PR Newswire)
25.07.17	Gainers & Losers Of July 24: WBMD, NDRM, PETS, AEZS, VTVT... (RTTNews)
24.07.17	AcelRx Pharmaceuticals to Hold Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2nd (PR Newswire)
18.07.17	Biotech Stocks Growing Faster Than Other Sectors Fueled by Breakthroughs in R&D and Clinical Trials (PR Newswire)
18.07.17	Biotech Stocks Growing Faster Than Other Sectors Fueled by Breakthroughs in R&D and Clinical Trials (PR Newswire)
18.07.17	Gainers & Losers Of July 17: ACRX, QDEL, AKCA, SGMO, SUPN... (RTTNews)
08.06.17	Gainers & Losers Of June 7: NH, CRUS, PTCT, ANAB, ACRX... (RTTNews)
01.06.17	AcelRx Pharmaceuticals' ZALVISO Recognized for Innovative Design with Prestigious Red Dot Award (PR Newswire)
31.05.17	AcelRx Pharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference (PR Newswire)
08.05.17	AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
27.04.17	Cover Of New Diary Of A Wimpy Kid Book Revealed By Jeff Kinney To Fans Worldwide At Livestreamed Carnegie Hall Event Hosted By ABRAMS (PR Newswire)
26.04.17	AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on Monday, May 8th, 2017 (PR Newswire)
13.04.17	AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV, Transdermal and Sublingual Patient-Controlled Analgesia Systems (PR Newswire)
06.04.17	AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results at ASRA's Annual Regional Anesthesiology and Acute Pain Medicine Meeting (PR Newswire)
28.03.17	European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30 mcg Tablet (ARX-04) for Moderate-to-Severe Acute Pain (PR Newswire)
17.03.17	AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March and April (PR Newswire)
16.03.17	AcelRx Pharmaceuticals Presents Efficacy and Pharmacokinetics of DSUVIA™ at Upcoming Congresses (PR Newswire)
02.03.17	AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results (PR Newswire)
01.03.17	AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in March (PR Newswire)
28.02.17	LJPC Climbs 76%, VTVT On Track, Eventful October Awaits ACRX, ATRS (RTTNews)
27.02.17	AcelRx Pharmaceuticals' New Drug Application for DSUVIA Accepted for Filing with PDUFA Date of October 12, 2017 (PR Newswire)
23.02.17	AcelRx Pharmaceuticals to Hold Annual 2016 Financial Results Conference Call and Webcast on Thursday, March 2nd, 2017 (PR Newswire)
16.02.17	AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer (PR Newswire)
13.02.17	AcelRx Pharmaceuticals Presentation at JAB Burn Symposium Highlights Potential of DSUVIA™ for Use in Burn Victims with Moderate-to-Severe Acute Pain (PR Newswire)
07.02.17	AcelRx Pharmaceuticals to Participate at Four Upcoming Investor Events in February (PR Newswire)
08.01.17	AcelRx Provides Guidance On 2017 Milestones For ARX-04 In U.S. (RTTNews)
08.01.17	AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain (PR Newswire)
08.01.17	AcelRx Pharmaceuticals Announces DSUVIA™ as Brand Name for ARX-04 in the United States (PR Newswire)
13.12.16	AcelRx Pharmaceuticals Submits New Drug Application for ARX-04 for the Treatment of Moderate-To-Severe Acute Pain (PR Newswire)
28.11.16	AcelRx Pharmaceuticals Updates Agenda for Analyst & Investor Event Focusing on Innovative Therapies for Treatment of Acute Pain (PR Newswire)
16.09.16	ARLZ Gets FDA Nod, ACRX Scores Hat Trick, OTIC On Watch, No Relief For NVAX (RTTNews)
16.09.16	MÄRKTE USA/Aktien nach Datenflut erholt - Apple-Rally geht weiter (Dow Jones)
15.09.16	MÄRKTE USA/Aktien nach Datenflut erholt - Apple-Rally geht weiter (Dow Jones)
15.09.16	MÄRKTE USA/Etwas fester nach Datenflut - Apple-Aktie läuft weiter (Dow Jones)
15.09.16	Data Boosts AERI, FDA Panel Snubs SPPI, D-Day For ACRX Today, VTAE Abuzz (RTTNews)
16.08.16	AUPH Loses Aura, PETX Scores Hat Trick, ACRX Meets Trial Goal (RTTNews)
08.03.16	ACRX For The Long Haul, CLDX Disappoints, NVIV Inspires, MRNS Awaits Data (RTTNews)
29.10.15	EARNINGS SUMMARY: Details of AcelRx Pharmaceuticals Inc. Q3 Earnings Report (RTTNews)
09.10.15	VSTM's Blues Continue, CLCD Well Armed, Titan Makes Big Leap, NYMX On Watch (RTTNews)
07.10.15	ADXS Plunges On Clinical Hold, AVXL Prepares For Uplisting, Nu Skin Peeling Off (RTTNews)
22.09.15	AcelRx: EU Oks Zalviso For Management Of Acute Post-operative Pain In Adults (RTTNews)
21.09.15	AcelRx Announces Sale Of Zalviso In EU By Grunenthal To PDL BioPharma (RTTNews)
10.09.15	RVNC Works It Out, ONCE Awaits Data, AKBA, VTAE Make Big Moves, TTPH Doused (RTTNews)
09.09.15	AcelRx: ARX-04 Phase 3 Trial Meets Endpoints For Moderate-to-Severe Acute Pain (RTTNews)
04.08.15	ISIS Does It Again, LXRX Shines On TELESTAR Data, ACRX Awaits EC Approval (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu AcelRx Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten